First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy
Clinical trial NCT03798535 · COMPLETED
Trial details
- NCT number
- NCT03798535
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2018-12-19
- Primary completion
- 2024-07-16
- Enrollment
- 1156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.